Table 2.
Resveratrol improved left ventricular function in ISO-treated rats and reduced left ventricular hypertrophy.
| Baseline | C | RES | ISO | ISO + RES | |
|---|---|---|---|---|---|
| EF (%) | 75.62 ± 0.87 | 71.70 ± 1.61 | 72.47 ± 1.69 | 56.96 ± 1.43# | 67.49 ± 1.14∗ |
| Septum (mm) | 1.63 ± 0.05 | 1.65 ± 0.10 | 1.61 ± 0.03 | 1.82 ± 0.03# | 1.70 ± 0.02∗ |
| PW (mm) | 1.57 ± 0.03 | 1.59 ± 0.07 | 1.59 ± 0.03 | 1.81 ± 0.06# | 1.60 ± 0.02∗ |
| LVIDd (mm) | 8.19 ± 0.11 | 8.44 ± 0.22 | 8.43 ± 0.17 | 7.88 ± 0.12 | 8.41 ± 0.23 |
| LVIDs (mm) | 4.42 ± 0.08 | 4.85 ± 0.09 | 4.69 ± 0.19 | 5.70 ± 0.2# | 4.90 ± 0.12∗ |
| LVEDV (μl) | 364.23 ± 10.38 | 393.36 ± 19.32 | 386.40 ± 16.82 | 365.54 ± 6.64 | 401.59 ± 18.63 |
| LVESV (μl) | 88.83 ± 4.40 | 109.9 ± 4.53 | 106.14 ± 7.26 | 157.71 ± 7.29# | 130.27 ± 6.69∗ |
| LV mass (mg) | 994.1 ± 21.8 | 1035.31 ± 59.79 | 1038.38 ± 44.44 | 1239.14 ± 76.5# | 1041.85 ± 35.50∗ |
C: control group; RES: resveratrol group; ISO: isoproterenol-treated group; ISO + RES: ISO + resveratrol group. EF: ejection fraction; LVESV: left ventricular end-systolic volume; LVEDV: left ventricular end-diastolic volume; LVIDd: diastolic left ventricular inner diameter; LVIDs: systolic left-ventricular inner diameter. The results are expressed as mean ± SEM. #P < 0.05 versus control. ∗P < 0.05 versus ISO.